Pre-Emptive Donor Lymphocyte Infusion Corrects Deficiencies in the T-Cell Repertoire after Allogeneic Haematopoietic Stem Cell Transplantation with Lymphocyte-Depletion for Acute Myeloid Leukaemia and Myelodysplastic Syndromes

Barber, Linda D.; Rakhayes, Monera Al; Golding, Josephine P.; Feliu, Jesús; Perez-Abellan, Pilar; Flóró, Lajos; Clay, Jennifer; Pagliuca, Antonio; Farzaneh, Farzin; Krishnamurthy, Pramila; Potter, Victoria; Mufti, Ghulam J.

doi:10.1016/j.bbmt.2015.11.499

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, in patients receiving unmodified DLI, the 1 year event-free survival (EFS) was 0%, compared with 27% in the T REG- depleted group. Increased proportions of naïve (T N ) and T central memory (T CM ) cells, and reductions in T effector memory (T EM ) and terminal effectors were observed 49 . Overall, the results from this small trial suggest that CD25-depleted DLI may be somewhat more effective than unmodified DLI for the management of relapsed acute leukemia post-allo-HSCT.…”

Section: Selective Depletion and Allodepleted DLImentioning

confidence: 99%

Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!

Grant

Bollard

2018

Blood Reviews

View full text Add to dashboard Cite

Cell therapy currently performs an important role in the treatment of patients with various hematological malignancies. The response to the cell therapy is regulated by multiple factors including the patient's immune system status, genetic profile, stage at diagnosis, age, and underlying disease. Cell therapy that does not require genetic manipulation can be mediated by donor lymphocyte infusion strategies, selective depletion in the post-transplant setting and the ex vivo expansion of antigen-specific T cells. For hematologic malignancies, cell therapy is contributing to enhanced clinical responses and overall survival and the immune response to cell therapy is predictive of response in multiple cancer types. In this review we summarize the available T cell therapeutics that do not rely on gene engineering for the treatment of patients with blood cancers.

show abstract

Section: Selective Depletion and Allodepleted DLImentioning

confidence: 99%

Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!

Grant

Bollard

2018

Blood Reviews

View full text Add to dashboard Cite

show abstract

“…Unmodified DLI [35][36][37][38][39][40][41][42][43][44] Infusion of donor lymphocytes to mount GVT response Modified DLI [45][46][47][48][49]71 Depletion of DLI subpopulations, T REG , naive T cells, to select for most potent CTLs…”

Section: Treatment Approach Descriptionmentioning

confidence: 99%

Developing T-cell therapies for lymphoma without receptor engineering

Grant

Bollard

2017

Blood Advances

View full text Add to dashboard Cite

T-cell therapy has emerged from the bench for the treatment of patients with lymphoma. Responses to T-cell therapeutics are regulated by multiple factors, including the patient’s immune system status and disease stage. Outside of engineering of chimeric antigen receptors and artificial T-cell receptors, T-cell therapy can be mediated by ex vivo expansion of antigen-specific T cells targeting viral and/or nonviral tumor-associated antigens. These approaches are contributing to enhanced clinical responses and overall survival. In this review, we summarize the available T-cell therapeutics beyond receptor engineering for the treatment of patients with lymphoma.

show abstract